Project Details
Description
A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell
| Status | Finished |
|---|---|
| Effective start/end date | 3/1/07 → 2/28/11 |
Funding
- OSI Pharmaceuticals, Inc.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.